12. Special patients and multidisciplinary dentistry
PBM in medically complex care
PBM does not reduce systemic risk. In medically complex patients, the OHDR risk pathway runs before, not after, the PBM decision.
Supportive care in oncology, impaired healing, frailty and polypharmacy — always inside a coordinated care plan.
Symptom and healing support where systemic conditions limit conventional options; the systemic condition itself remains unmodified.
Tissue and anatomical targets
- • Oral mucosa in oncology supportive care
- • Surgical sites with impaired healing
- • Painful mucosa in frail patients
Clinical objectives
- • Supportive symptom management
- • Healing support within a coordinated plan
- • Comfort in patients with limited treatment tolerance
Dosimetric reasoning
- • Follow the institutional supportive-care protocol where one exists; do not improvise oncology dosimetry.
Technique
- • Field-based mucosal application; strict infection control in immunosuppressed patients.
Limitations
- • Antiresorptive, immunosuppression and radiotherapy risks persist unchanged.
- • Photosensitising medication must be reviewed.
- • Some situations require medical clearance before any elective procedure.
Safety
- • Run the OHDR pathway: assessment → risk classification → clinical decision → PBM decision → treatment → monitoring.
- • Document medical coordination.
Common errors
- • Assuming PBM makes an unsafe procedure safe.
- • Skipping medication review.
Clinical pearls
- • PBM changes symptoms, not systemic risk classification.
Indications and evidence level
Biphasic dose-response, irradiance and light–tissue interaction were established there. Now apply them to this specialty's tissue thickness, vascularity and inflammatory state.
State the diagnosis and clinical objective before selecting a single parameter, and record the evidence level supporting what you tell the patient.
Eye protection for patient, operator and assistant. PBM does not remove the need for diagnosis, clinical judgment or medical coordination.
Knowledge checkpoint
Patient on IV antiresorptive therapy needs an extraction. What does PBM change in the risk assessment?
Chapter summary
- • The biological principles are unchanged; the target, objective and strategy change.
- • Etiological treatment first; PBM as adjunct where justified.
- • Only claim what the evidence level supports.
- • Systematic reviews and meta-analyses on PBM in dentistry — to be curated by the academic team.
- • International PBM/laser safety guidance applicable in the institution's jurisdiction.
- • Institutional clinical protocol documentation (where authorised).
Linked educational cases
Educational content only. These algorithms are educational decision-support tools and never autonomous medical decision-makers. Clinical decisions remain the responsibility of the treating professional. Certification within OHDR Study™ is not a university award unless an authorised institution has been formally configured.